Trial Profile
An open-label, multicenter phase II study to assess the response of subjects with metastatic breast cancer previously treated with anthracycline and taxane therapy with or without capecitabine to ZD6474 [vandetanib] (100-mg or 300-mg daily oral dose)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Aug 2016
Price :
$35
*
At a glance
- Drugs Vandetanib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors AstraZeneca
- 17 Oct 2006 Status change
- 17 Sep 2005 New trial record.